Stiff-Person Syndrome (SPS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Stiff-Person Syndrome (SPS) Market Outlook

Thelansis’s “Stiff-Person Syndrome (SPS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Stiff-Person Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Stiff-Person Syndrome (SPS) Overview

Stiff person syndrome (SPS) encompasses a spectrum of disorders characterized by progressively increasing axial rigidity accompanied by intermittent, painful spasms. This condition predominantly affects females and may arise idiopathically or secondary to autoimmune disorders or paraneoplastic conditions, accounting for approximately 5% of cases. Variants within this syndrome include stiff limb syndrome, jerking stiff person syndrome, and progressive encephalomyelitis with rigidity and myoclonus (PERM). The clinical course of SPS is variable, often ameliorating during sleep but exacerbating with movement, sensory stimuli, or emotional stress. Patients may also experience spasms and myoclonic jerks. In SPS, anti-glutamic acid decarboxylase (anti-GAD) autoantibodies are detected in 50–90% of cases, with other associated autoantibodies, including anti-amphiphysin and anti-glycine receptors. The presence of anti-GAD antibodies is predominantly linked to autoimmune diseases such as type 1 diabetes mellitus. In contrast, anti-amphiphysin and anti-glycine receptor antibodies are frequently associated with solid tumors. Paraneoplastic SPS often involves both limbs and may be accompanied by sensory neuronopathy. Notably, anti-glycine receptor antibodies can yield false positives outside the phenotypic spectrum of SPS and PERM, as seen in conditions like optic neuritis and epilepsy. Anti-amphiphysin antibodies may also be present in PERM, marked by altered consciousness, brainstem manifestations, myoclonus, cerebellar ataxia, and diffuse rigidity. Treatment for SPS is categorized into symptomatic management and disease-modifying or immunotherapeutic approaches. Typically, these therapeutic strategies are employed in combination based on disease severity. Symptomatic treatment, the cornerstone of initial therapy, aims to reduce stiffness, rigidity, and painful muscle spasms through agents that enhance GABAergic activity, including benzodiazepines, baclofen, gabapentin, and vigabatrin. Diazepam is frequently the first-line symptomatic agent for SPS, though tolerance and dependency on benzodiazepines may develop, diminishing their effectiveness over time. Intrathecal baclofen has shown efficacy in certain patients, while other muscle relaxants such as dantrolene and tizanidine are also utilized. Additionally, the management of coexisting seizures and psychiatric comorbidities involves the use of antiepileptic and antidepressant medications, respectively. Disease-modifying therapy involves immune modulation to reduce or eliminate autoantibodies. Intravenous immunoglobulin (IVIG) has demonstrated significant efficacy as an immunotherapy for SPS, providing clinical improvement for up to one year following a standard course of five sessions.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: